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The translocator protein (TSPO) is an important target for imaging focal neuroinﬂammation in diseases such
as brain cancer, stroke and neurodegeneration, but current tracers for non-invasive imaging of TSPO have
important limitations. We present the synthesis and evaluation of a novel 3-ﬂuoromethylquinoline-2-
carboxamide, AB5186, which was prepared in eight steps using a one-pot two component indium(III)-
catalysed reaction for the rapid and eﬃcient assembly of the 4-phenylquinoline core. Biological
assessment and the implementation of a physicochemical study showed AB5186 to have low nanomolar
aﬃnity for TSPO, as well as optimal plasma protein binding and membrane permeability properties.
Generation of [18F]-AB5186 through 18F incorporation was achieved in good radiochemical yield and
subsequent in vitro and ex vivo autoradiography revealed the ability of this compound to bind with
speciﬁcity to TSPO in mouse glioblastoma xenografts. Initial positron emission tomography imaging of a
glioma bearing mouse and a healthy baboon support the potential for [18F]-AB5186 use as a radiotracer
for non-invasive TSPO imaging in vivo.Introduction
Positron emission tomography (PET) is now used routinely for
non-invasive imaging of human anatomy and physiology.1 The
development of PET technology and instrumentation has
allowed for the in vivo study of biological processes at the
molecular and cellular levels.2,3 These studies have resulted in
numerous healthcare applications such as clinical diagnosis
and information on prognosis for many diseases associated
with neurology, oncology and cardiology.1,2 PET imaging has
also been used during the drug discovery process for under-
standing drug action and establishing dosage regimens and
treatment strategies. The continued growth and increasingy of Glasgow, The Joseph Black Building,
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Chemistry 2015importance of PET imaging has driven the need for new
imaging probes and chemical methods for the rapid radio-
labelling of compounds. Substantial progress has been made in
developing eﬃcient transformations for the incorporation of
short-lived positron-emitting isotopes,4,5 however a signicant
limitation that still exists is the discovery of new imaging agents
that can bind with high aﬃnity and specicity to key biological
targets.
One such important biological target is the translocator
protein (TSPO; 18 kDa), an outer mitochondrial membrane
protein found in many of the major organs including lung,
heart, liver, kidney and brain.6,7 In healthy brain tissue, TSPO is
expressed at low concentrations, however in response to focal
brain injury or neurodegeneration, levels of TSPO expression
increase dramatically. This change has been directly linked to
activation of the brain's resident immune cells, microglia,8
which release pro-inammatory cytokines during infection or
injury.9 Microglial activation and associated TSPO over-
expression are therefore an indicator of the early stages of
neuroinammation associated with brain tumours10 and
stroke-induced brain injury11 as well as in human neurode-
generative diseases such as Alzheimer's disease, Huntington's
disease, Parkinson's disease and multiple sclerosis.12 For this
reason, TSPO is considered an excellent target for under-
standing and treating diseases associated with
neuroinammation.
The overexpression of TSPO in active disease states has
resulted in the development of many high aﬃnity agents for inChem. Sci.
Fig. 1 Imaging agents for TSPO; [11C]-PK11195 (1), [18F]-DPA714 (2)
and [18F]-FEDAA1106 (3).
Fig. 2 Quinoline-2-carboxamides 4, 5 and 6.
Scheme 1 Synthesis of AB5186 6. Reagents and conditions: (a) InCl3,
80 C, 3 h, 100%; (b) NaBH4, THF, MeOH, D, 15 h, 93%; (c) MnO2,
CHCl3, rt, 4 h, 83%; (d) (i) LiAlH4, THF, 0 C, 3 h; (ii) 10% Pd/C, MeOH, rt,
15 h, 77%; (e) MnO2, CHCl3, rt, 4 h, 92%; (f) Et2NH, Me3Al, CH2Cl2, D, 15
h, 61%; (g) SOCl2, CH2Cl2, D, 24 h, 100%; (h) KF, 18-crown-6, MeCN, D,
24 h, 60%.
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View Article Onlinevivo imaging.12,13 The mostly widely used ligand is the iso-
quinoline carboxamide [11C]-PK11195 1 (Fig. 1), which has been
used to study patients with various disorders such as dementia,
Parkinson's disease and stroke.7,12–14 Despite its widespread use
[11C]-PK11195 1 has a number of signicant limitations as it has
poor brain uptake and displays a low signal to noise ratio.12,13 In
addition, labelling of this probe with the 11C radionuclide is
challenging due to this isotope being short lived with a half-life
(t1/2) of just 20.4 min. The
18F radionuclide has a longer t1/2 of
110 min and therefore is much more favourable and less
restricting for patient imaging. Eﬀorts have focused on the
development of second generation TSPO imaging agents with
improved physicochemical properties, such as [18F]-DPA714 2
and [18F]-FEDAA1106 3.12,13 However, with the exception of
PK11195, the in vitro binding of more recently developed TSPO
PET ligands to human brain tissue is variable between diﬀerent
individuals such that they can be classied into high-aﬃnity,
low-aﬃnity or mixed-aﬃnity “binders”.15 This variability in the
aﬃnities of the ligands for TSPO across diﬀerent individuals
limits quantitative comparison of TSPO expression between
subjects in PET studies.
We therefore initiated a programme of research with the aim
of developing an eﬀective TSPO imaging agent for general use in
humans.16 Inspired by the work of Cappelli and co-workers,17 we
focused on quinoline-2-carboxamides that are structurally
similar to PK11195 1. Our studies revealed the rigidity and steric
factors that necessitate eﬃcient binding of compounds to
TSPO.16 Based on this understanding, we discovered 3-iodo-
methylquinoline-2-carboxamide 4 and 4-(2-iodophenyl)quino-
line-2-carboxamide 5 as high aﬃnity agents for TSPO with the
potential to act as single photon emission computed tomog-
raphy (SPECT) tracers (Fig. 2). Our work on the development of
SPECT imaging agents for various biological targets has shown
that certain negative physicochemical characteristics such as
high plasma protein binding, can be due to the lipophilic
nature of the iodine atom.16,18,19 Therefore, it was proposed that
by using some of the key structural features identied from
quinoline-2-carboxamides 4 and 5 in combination with a lessChem. Sci.lipophilic uorine atom would result in an eﬀective [18F]-PET
imaging agent for TSPO.
We now report the synthesis, biological evaluation and
physicochemical properties of novel 3-uoromethylquinoline-2-
carboxamide AB5186 6 (Fig. 2). We describe the incorporation of
the longer-lived radioactive uorine (18F: t1/2 ¼ 110 min) into
AB5186 and subsequent in vitro and ex vivo autoradiography, as
well as initial kinetic PET data obtained using mouse intracra-
nial xenogra models of human glioblastoma. The brain PET
kinetics and the metabolic prole of [18F]-AB5186 6 obtained
from a single healthy baboon are also presented.Results and discussion
The 3-uoromethylquinoline-2-carboxamide, AB5186 6 was
prepared in eight steps as shown in Scheme 1. Previous
synthetic routes to this class of compounds have used a
Friedla¨nder condensation between 2-aminobenzophenone (7)
and ethyl 4-chloroacetoacetate,16,17,20 followed by an acid-medi-
ated lactonisation which produced 10.21 However, this acid-
mediated lactonisation requires nine-days for completion. To
circumvent this, a new approach was developed for the rapid
preparation of lactone 10. 4-Phenylquinoline 9 was prepared in
quantitative yield using a one-pot two component, indium(III)-
catalysed reaction between 2-aminobenzophenone (7) andThis journal is © The Royal Society of Chemistry 2015
Scheme 2 Radiosynthesis of [18F]-AB5186 6.
Fig. 3 (a) H&E stained section of a CD1 nude mouse brain bearing an
orthotopic G7 human glioblastoma xenograft which stains dark purple
and distorts the normal brain. Representative autoradiograms showing
(b) total binding of [18F]-AB5186 6, and (c) non-speciﬁc binding in the
presence of unlabelled PK11195 1.
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View Article Onlinediethyl acetylenedicarboxylate (8).22 Reduction of diester 9 with
sodium borohydride gave the corresponding 3-lactol interme-
diate which was subsequently oxidised to lactone 10 in high
yields and more importantly, a relatively short overall reaction
time. From lactone 10, a more typical sequence of reactions
were utilised to switch the lactone position from C-3 (10) to C-2
(11).21 Trimethylaluminium-mediated incorporation of diethyl-
amine and consecutive formation of the 3-hydroxymethyl group
gave 12 in 61% yield. Chlorination of the hydroxymethyl group
followed by substitution with potassium uoride completed the
synthesis of AB5186 6.
Competition binding assays using rat brain homogenates to
measure the displacement of [3H]-PK11195 revealed that
AB5186 6 has low nanomolar aﬃnity for TSPO with a Ki value of
2.8 nM, similar to that for PK11195 1 (Table 1). As observed with
other quinoline-2-carboxamides of this class (e.g. 4), the pres-
ence of the 3-uoromethyl group likely restricts rotation of the
amide, resulting in potent binding to the proposed H-bond
donor pocket of TSPO.6
The key physicochemical parameters of AB5186 6, perme-
ability (Pm), membrane partition coeﬃcient (Km) and
percentage of plasma protein binding (%PPB) were determined
by high-performance liquid chromatography (HPLC) methods
(Table 1).23 Using the established limits of these parameters
(Pm < 0.5, Km < 250, %PPB < 95%) for predicting in vivo
performance of an imaging agent,23 AB5186 6 was found to have
optimal physicochemical properties for use as a molecular
imaging tracer. A Pm of 0.5 and %PPB of 89.7% indicate that
AB5186 6 has the potential to eﬀectively penetrate the blood
brain barrier (BBB), while a Km of 154.3 suggests that AB5186 6
will exhibit a desirable specic to non-specic binding ratio
($2).23 As AB5186 6 contains a uoroalkyl group, a potential
alkylating agent, the stability of this compound was examined
in simulated physiological conditions. Incubation of the
compound in phosphate buﬀered saline at pH 7.4 and 37 C
showed minimal decomposition (0.03%) aer 6 hours.24 The
combination of a relatively strong C–F bond and the presence of
bulky di-ortho-substituents impart a good level of stability.
Encouraged by these results, a radiouorination method for
the preparation of [18F]-AB5186 6 was developed which involved
a halogen exchange reaction. Chloride 13, the penultimate
compound in the cold synthesis of 6 (Scheme 1) was treated
with [18F]-potassium uoride (607  75 MBq; n ¼ 7), Kryptox®
and potassium carbonate at 100 C for 12 min (Scheme 2). Aer
HPLC purication, [18F]-6 was isolated in a 38  19% decayTable 1 Binding aﬃnity and physicochemical values of PK11195 1 and
AB5186 6
Compound Ki
a (nM) Pm
b Km
b %PPBc
PK11195 1 3.1  1.5 0.7 229.4 91.5
AB5186 6 2.8  0.8 0.5 154.3 89.7
a Ki values are the mean  the standard deviation of three independent
experiments. b Determined using immobilised articial membrane
(IAM) column. c Determined using human serum albumin (HSA)
coated column.
This journal is © The Royal Society of Chemistry 2015corrected radiochemical yield (RCY) and in 118  14 min (n ¼
7). The radiochemical purity of [18F]-AB5186 6 was measured as
>99%, with a specic activity of 0.6  0.2 Ci mmol1. Identi-
cation of the product was conrmed using HPLC by co-injection
with a sample of unlabelled AB5186 6.
An initial investigation of the potential of [18F]-AB5186 6 to
bind to TSPO in brain involved in vitro autoradiography using a
G7 orthotopic mouse model of human glioblastoma.25 Autora-
diography allows the distribution of a radiolabelled compound
to be visualised in intact biological tissue sections.26 The loca-
tion of the tumour was identied by staining sections withFig. 4 Representative immunohistochemistry images of a CD1 nude
mouse brain bearing an orthotopic U87MG-luc2 glioma xenograft
stained for: (a) Ki67 (cell proliferation marker), (b) TSPO, and (c)
microglia (Iba1). Brown staining signiﬁes presence of marker.
Chem. Sci.
Fig. 5 Representative coronal brain autoradiograms obtained after
injecting intracranial U87MG-Luc2 glioma bearing mice with (a)
vehicle or (b) 1 mg kg1 PK11195 followed by [18F]-AB5186 10min later.
Brains were harvested for sectioning 20 min after tracer injection.
Black arrows indicate tumour hotspots. (c) Ratios of tumour to
contralateral tissue optical densities in the vehicle (n ¼ 4) and PK11195
(n ¼ 4) pre-treatment cohorts (P ¼ 0.0002). Error bars represent the
standard error of mean.
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View Article Onlinehaematoxylin and eosin, H&E, (Fig. 3a)27 which revealed the
tumour to be large and unilateral. The in vitro autoradiograms
showed markedly increased total binding of [18F]-AB5186 6
within the tumour tissue compared to the contralateral side
(Fig. 3b). This binding was displaceable in the presence ofFig. 6 Averaged PET images of a U87MG-Luc2 glioma bearing mouse br
min averaged, and (c) 81–120min averaged; 120min dynamic scan. White
followingmanual co-registration of the CT image with the PET image. (d)
Time–activity curves of the tracer in the tumour and contralateral br
expressed as a ratio of the tumour to contralateral SUVs.
Chem. Sci.excess unlabelled PK11195 1 (Fig. 3c) with 76% displacement in
the tumour tissue compared to only 23% in the contralateral
region. Displacement of [18F]-AB5186 6 by the TSPO ligand
PK11195 conrms the in vitro specicity of the tracer for TSPO
in brain tissue.
To investigate the behavior of [18F]-AB5186 6 in vivo, ex vivo
autoradiography was performed using mice bearing a U87MG-
Luc2 orthotopic model of human glioblastoma. Animals were
pre-treated with either vehicle (n ¼ 4) or 1 mg kg1 unlabelled
PK11195 (n ¼ 4) administered intravenously 10 min prior to
[18F]-AB5186 6 intravenous injection. Animals were killed and
brains were removed 20 min aer the radiotracer was given and
frozen. Cryostat sections were then used to generate autora-
diograms. Histological evaluation of the intracranial
U87MG-Luc2 mouse model showed a large number of prolif-
erating cells (Fig. 4a), TSPO expression (Fig. 4b) and microglia
(Fig. 4c) within the main tumour mass. The non-tumour
bearing contralateral side of the brain lacked proliferating cells
and minimal TSPO expression and immunolabelled microglia
were visible (data not shown). Under normal circumstances
microglia express low levels of TSPO in the brain. However, in
response to injury microglia become activated and TSPO
expression is greatly increased.8 However, in this case it is
presumed that the cancer cells contribute to the majority of the
TSPO overexpression.28 The total binding of [18F]-AB5186 6 was
substantially higher in the tumour tissue compared to the
contralateral region (Fig. 5a and c). The binding was signi-
cantly reduced (P ¼ 0.0002) in animals treated with unlabelled
PK11195 (Fig. 5b and c) conrming the in vivo specicity of
[18F]-AB5186 6 for TSPO.ain following [18F]-AB5186 injection: (a) 0–40 min averaged, (b) 41–80
arrows indicate tumour hotspots. The brain was deﬁned using the skull
H&E staining showing location of the tumour which stains dark blue. (e)
ain regions obtained from manually deﬁned VOIs. (f) Tracer kinetics
This journal is © The Royal Society of Chemistry 2015
Fig. 7 (a) MRI and averaged PET image (0–60min; 240min dynamic scan) of healthy baboon brain following [18F]-AB5186 6 injection. (b) Whole
brain time activity curve for the tracer in the baboon brain. (c) Parent fraction proﬁle of [18F]-AB5186 6 over time following bolus injection into
baboon.
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View Article OnlineIn order to investigate the potential of [18F]-AB5186 6 as a
PET tracer for TSPO a dynamic PET scan was performed using
the Albira imaging system (Carestream Molecular Imaging,
USA) in a single mouse bearing an intracranial U87MG-Luc2
tumour for 120 min aer intravenous administration of the
tracer. Postmortem histological examination of the brain
collected at the end of the scan was conducted to visualise the
anatomical location of the tumour. Following reconstruction,
the entire dynamic PET image wasmanually co-registered to key
anatomical structures of the CT (i.e. the spine, the front limbs
and the eye sockets). The skull was then used to dene the brain
region and the PET signal outside of this region was masked
which allowed for greater clarity when identifying the tumour
hotspot. Binding of [18F]-AB5186 6 to the tumour was clearly
visible in the PET scan (Fig. 6a–c) whose location correlated to
that revealed by histology (Fig. 6d). Time–activity curve analysis
of the PET data revealed greater amounts of [18F]-AB5186 6 in
the tumour versus the contralateral region during the early
portion of the scan (Fig. 6e and f). These data support the ability
of [18F]-AB5186 6 to image TSPO in vivo under pathological
conditions.
In order to show that [18F]-AB5186 6 can penetrate into healthy
brain tissue, a 240 min baseline dynamic PET scan was per-
formed of the head of a healthy baboon. Following PET recon-
struction and co-registration to an MRI (Fig. 7a), a time–activity
curve for the tracer in the whole brain was established (Fig. 7b).
The peak standardised uptake values (SUV) in the baboon brain
was 1.67 suggesting that [18F]-AB5186 6 can eﬀectively cross the
intact BBB. Metabolic analysis of arterial blood samples taken
from the baboon during PET imaging (Fig. 7c) revealed moderateThis journal is © The Royal Society of Chemistry 2015metabolism of [18F]-AB5186 6, with 29.8% of the parent still intact
60 minutes post-injection (Fig. 7c).
Conclusions
We have developed a novel 3-uoromethylquinoline-2-carbox-
amide, AB5186 6, which has low nanomolar aﬃnity for TSPO
and optimal physicochemical properties. Radiouorination
methodology was developed allowing eﬃcient access to the
radiolabelled version of this compound ([18F]-AB5186 6). In vitro
and ex vivo autoradiography studies in mouse models of human
glioblastoma, showed specic binding of [18F]-AB5186 to TSPO
in tumour tissue. In addition, [18F]-AB5186 6 exhibited the
ability to image TSPO in an intracranial glioma bearing mouse
and to penetrate the intact BBB in a non-human primate. Taken
together these ndings support the potential for further devel-
opment of [18F]-AB5186 as a PET imaging agent for TSPO in the
brain.
Recently, Pike and co-workers reported low sensitivity of
[11C]-labelled azaisosteres of [11C]-PK11195 1 to TSPO single
nucleotide polymorphism.29 We hypothesise that because of the
restricted rotation of the structure, [18F]-AB5186 6 will also
possess low sensitivity to this polymorphism. These properties
in combination with the longer-lived 18F radioisotope (18F: t1/2¼
110 min versus 11C: t1/2 ¼ 20.4 min) should allow the general
application of [18F]-AB5186 6 in preclinical and clinical imaging
studies of brain pathologies associated with TSPO over-
expression. Further evaluation of the binding prole of
[18F]-AB5186 6 in human tissue is currently underway in our
laboratories.Chem. Sci.
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